Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-κB and TGF-β pathways.

Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-κB and TGF-β pathways.
复制标题

DOI:
10.1111/jcmm.13334
复制
发表时间:
2018-01
影响因子:
5.3
通讯作者:
Yang JY
Yang JY
中科院分区:
医学2区
文献类型:
--
作者:
Li Y;Wang LH;Zhang HT;Wang YT;Liu S;Zhou WL;Yuan XZ;Li TY;Wu CF;Yang JY

文献摘要

参考文献

被引文献

相似文献

晚期肝细胞癌(HCC)由于转移风险高且缺乏有效的治疗方法,通常生存率较低。双硫仑 (DSF) 在体外和体内均具有铜 (Cu) 依赖性抗癌特性。目前的工作旨在探讨 DSF/Cu 在体外和体内对 HCC 细胞的抗转移作用和分子机制。结果表明,DSF抑制HCC细胞的增殖、迁移和侵袭。 Cu 提高了 DSF 的抗转移活性,而单独使用 Cu 则没有效果。此外,DSF/Cu 抑制 NF-κB 和 TGF-β 信号传导,包括 NF-κB 亚基的核转位和 Smad4 的表达,导致 Snail 和 Slug 下调,从而促进表型上皮间质转化 (EMT)。最后,DSF/Cu 不仅在皮下肿瘤模型中而且在原位肝转移试验中都能抑制 Hep3B 细胞的肺转移。这些结果表明,DSF/Cu 通过 NF-κB 和 TGF-β 信号传导抑制肝癌的转移和 EMT。我们的研究表明 DSF/Cu 具有治疗用途的潜力。
Late‐stage hepatocellular carcinoma (HCC) usually has a low survival rate because of the high risk of metastases and the lack of an effective cure. Disulfiram (DSF) has copper (Cu)‐dependent anticancer properties in vitro and in vivo. The present work aims to explore the anti‐metastasis effects and molecular mechanisms of DSF/Cu on HCC cells both in vitro and in vivo. The results showed that DSF inhibited the proliferation, migration and invasion of HCC cells. Cu improved the anti‐metastatic activity of DSF, while Cu alone had no effect. Furthermore, DSF/Cu inhibited both NF‐κB and TGF‐β signalling, including the nuclear translocation of NF‐κB subunits and the expression of Smad4, leading to down‐regulation of Snail and Slug, which contributed to phenotype epithelial–mesenchymal transition (EMT). Finally, DSF/Cu inhibited the lung metastasis of Hep3B cells not only in a subcutaneous tumour model but also in an orthotopic liver metastasis assay. These results indicated that DSF/Cu suppressed the metastasis and EMT of hepatic carcinoma through NF‐κB and TGF‐β signalling. Our study indicates the potential of DSF/Cu for therapeutic use.
DOI: 10.1371/journal.pone.0068597
发表时间: 2013
期刊: PloS one
影响因子: 3.7
作者:
Kumar M;Allison DF;Baranova NN;Wamsley JJ;Katz AJ;Bekiranov S;Jones DR;Mayo MW
通讯作者: Mayo MW
MiR-130a-3p 通过抑制吉西他滨耐药肝癌细胞中的 Smad4 调节细胞迁移和侵袭
DOI: 10.1186/s13046-016-0296-0
发表时间: 2016-01-27
期刊: Journal of experimental & clinical cancer research : CR
影响因子: --
作者:
Liu Y;Li Y;Wang R;Qin S;Liu J;Su F;Yang Y;Zhao F;Wang Z;Wu Q
通讯作者: Wu Q
DOI: 10.1158/0008-5472.can-05-3560
发表时间: 2006-02-15
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Deckers, M;van Dinther, M;ten Dijke, P
通讯作者: ten Dijke, P
DOI: 10.1042/bj0200232
发表时间: 1926-01-01
影响因子: 4.1
作者:
Hieger, I
通讯作者: Hieger, I
DOI: 10.1158/0008-5472.can-11-1194
发表时间: 2011-09-01
期刊: Cancer research
影响因子: 11.2
作者:
Javelaud D;Alexaki VI;Dennler S;Mohammad KS;Guise TA;Mauviel A
通讯作者: Mauviel A